IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Wollenberger, Louis V.

JOCKERS, et al.

Art Unit: 1635

Application No.: 10/774,721

Filed: February 9, 2004

Title: OLIGONUCLEOTIDES WHICH INHIBIT

EXPRESSION OF THE OB-RGRP PROTEIN

AND METHOD FOR DETECTING COMPOUNDS WHICH MODIFY THE INTERACTION BETWEEN PROTEINS OF THE OB-RGRP FAMILYAND THE LEPTIN

RECEPTOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

X (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or \square (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

George S. Jones, Reg. No. 38,508

Attorney/Agent for Applicant

Sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP

lacco timo c	، میام	oian (+)	inalda	thia h		_	
lease type a	pius :	sign (+)	mside	นาเร บ	NX.	~	~

Sheet

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known				
		В.		Application Number	10/774,721	
INFORMATION DISCLOSURE				Filing Date	02-09-2004	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	JOCKERS, ET AL	
				Group Art Unit	1635	
(use as many sheets as necessary)		Examiner Name	WOLLENBERGER, Louis V.			
theet	1	οf	2	Attorney Docket Number	EDAV/2003/0005 - LIS - ND	

				U.S. PATENT DOCI	JMENTS	
Examiner Initials	Cite No.1	U.S. Paten Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					<u> </u>	
					+ + -	
· · · · · · - · · · ·						
					+	
			- 		+ + + + + + + + + + + + + + + + + + + +	
		· · · · · · · · · · · · · · · · · · ·				

				FORE	IGN PATENT DOCUMENT	rs		
Examiner	Cite	F	Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials	No.1	Office ³	Number ⁴	Kind Code ⁵ (If known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6
					,			

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box 🛶	~

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/774,721
				Filing Date	02-09-2004
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	JOCKERS
OMIEMENT BY ATTEMANT				Group Art Unit	1635
(use as many sheets as necessary)			as necessary)	Examiner Name	WOLLENBERGER, Louis V.
Sheet	2	of	2	Attorney Docket Number	FRAV2003/0005 - US - NP

include name of the author (in CAPIT)	
item (book, magazine, journal, serial, sy	AL LETTERS), title of the article (when appropriate), title of the mposium, catalog, etc.), date, page(s), volume-issue number(s), city and/or country where published.
HIDEO MAKIMURA et al., Reducing hypoth decreases body weight without influencing f	nalamic AGRP by RNA interference increases metabolic rate and food intake, BMC Neuroscience (2002, pp. 1-6)

Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.





¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.